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ABSTRACT A long-standing issue in the field of signal transduction is to understand the 
cross-talk between receptor tyrosine kinases (RTKs) and heterotrimeric G proteins, two major 
and distinct signaling hubs that control eukaryotic cell behavior. Although stimulation of many 
RTKs leads to activation of trimeric G proteins, the molecular mechanisms behind this phe-
nomenon remain elusive. We discovered a unifying mechanism that allows GIV/Girdin, a bona 
fide metastasis-related protein and a guanine-nucleotide exchange factor (GEF) for Gαi, to 
serve as a direct platform for multiple RTKs to activate Gαi proteins. Using a combination of 
homology modeling, protein–protein interaction, and kinase assays, we demonstrate that a 
stretch of ∼110 amino acids within GIV C-terminus displays structural plasticity that allows 
folding into a SH2-like domain in the presence of phosphotyrosine ligands. Using protein–
protein interaction assays, we demonstrated that both SH2 and GEF domains of GIV are re-
quired for the formation of a ligand-activated ternary complex between GIV, Gαi, and growth 
factor receptors and for activation of Gαi after growth factor stimulation. Expression of a 
SH2-deficient GIV mutant (Arg 1745→Leu) that cannot bind RTKs impaired all previously 
demonstrated functions of GIV—Akt enhancement, actin remodeling, and cell migration. The 
mechanistic and structural insights gained here shed light on the long-standing questions sur-
rounding RTK/G protein cross-talk, set a novel paradigm, and characterize a unique pharma-
cological target for uncoupling GIV-dependent signaling downstream of multiple oncogenic 
RTKs.
ing networks that ultimately control cell fate (Liebmann and Bohmer, 
2000). In eukaryotes, two widely studied and distinct signaling path-
ways are the receptor tyrosine kinases (RTKs) and trimeric G proteins. 
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INTRODUCTION
Signal transduction pathways link internal and environmental signals 
to cellular responses. It is well known that various signaling path-
ways cross-talk at multiple levels to generate large, complex signal-
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2008), and tumor metastasis (Garcia-Marcos et al., 2011b). Despite 
the growing evidence, the structural or biochemical basis for how 
GIV might engage with multiple RTKs and modulate their down-
stream signals remains a mystery.
Here we show that GIV binds multiple RTKs via a unique C-termi-
nal stretch that reveals sequence-dependent structural plasticity by 
folding into a Src homology 2 (SH2) module. Thus GIV appears to 
be the first SH2-like adaptor of its kind to directly couple RTK activa-
tion to trimeric G protein activation via its intrinsic GEF activity.
RESULTS
GIV directly binds autophosphorylated cytoplasmic tails 
of multiple RTKs
We previously demonstrated that GIV is recruited to ligand-acti-
vated EGFR (Ghosh et al., 2010). To discern whether GIV can inter-
act directly with multiple ligand-activated RTKs, we tested the ability 
of the C-terminus of GIV to bind recombinant, autophosphorylated 
cytoplasmic tails of EGFR, VEGFR, and insulin receptor β (InsRβ) 
containing their respective kinase domains in pull-down assays. 
These three RTKs were chosen because we and others have demon-
strated that GIV modulates Akt signaling and triggers cell migration 
when any of these three receptors is activated by its respective li-
gand (Enomoto et al., 2005; Jiang et al., 2008; Kitamura et al., 2008; 
Garcia-Marcos et al., 2009, 2010, 2011a, 2012; Ghosh et al., 2010; 
Lin et al., 2011). We found that a purified ∼200–amino acid (aa)–long 
C-terminal fragment of GIV is sufficient for GIV to bind all three re-
combinant active RTKs (Figure 1a), demonstrating that GIV can di-
rectly bind multiple autophosphorylated RTKs via its C-terminus. 
Next we asked which autophosphorylated tyrosine on the RTK tail 
GIV binds. Among the various RTKs, we focused on EGFR for two 
reasons: 1) it is a prototype RTK, and 2) EGFR autophosphorylation 
is best characterized, with in-depth understanding of the function of 
each autophosphorylation site and the signaling intermediates/
adaptors that they recruit (Helin et al., 1991; Decker, 1993; Batzer 
et al., 1994; Okabayashi et al., 1994; Okutani et al., 1994).
On the basis of clues from our previous work (Ghosh et al., 2010), 
which showed that aa 1020–1210 of the cytoplasmic tail of EGFR 
are sufficient for binding to GIV-CT, we mapped the phosphoty-
rosine-binding site for GIV on the EGFR tail by focusing exclusively 
on four of the five known sites of receptor autophosphorylation—
Y1068, Y1086, Y1148, and Y1173—which are present within that 
stretch of EGFR. Owing to the existence of multiple EGFR isoforms, 
each with its unique numbering of amino acids, autophosphoryla-
tion sites were identified by the sequence flanking the tyrosines 
(Savage and Cohen, 1972; Margolis et al., 1989; Walton et al., 1990; 
Sorkin et al., 1991, 1992), and glutathione S-transferase (GST)–
tagged EGFR tail (EGFR-T) peptides were cloned such that each 
construct allowed isolated testing of one or two of these four sites 
of autophosphorylation at a given time (Figure 1b). As a negative 
control, we also tested another tyrosine, Y1114, which does not get 
phosphorylated in the intact EGFR either in kinase reactions in vitro 
or in cells after EGF stimulation (Margolis et al., 1989). These GST-
tagged EGFR-T peptides were purified, phosphorylated in in vitro 
kinase assays using recombinant EGFR kinase (Figure 1c), and sub-
sequently used in pull-down assays with recombinant GIV-CT. We 
found that GIV interacted exclusively with GST-EGFR-T peptides 
containing phosphotyrosine Y1148 or Y1173 (Figure 1d), indicating 
that GIV-CT specifically binds to EGFR peptides containing those 
two but not the other autophosphorylated (Y1068, and Y1086) or 
nonphosphorylatable (Y1114) tyrosines. Because purified recombi-
nant proteins were used in these protein–protein interaction assays, 
we conclude that the interaction between GIV’s C-terminus and the 
On binding of growth factors such as epidermal growth factor (EGF) 
or insulin, RTKs phosphorylate a variety of targets on tyrosines to 
propagate signals to the cell’s interior (Gschwind et al., 2004). 
Trimeric G proteins, on the other hand, are traditionally defined as 
molecular switches that transmit signals from a different class of 
membrane receptors, the seven-transmembrane (7TM) receptors, 
also known as G protein–coupled receptors (GPCRs; Marinissen and 
Gutkind, 2001; Mills and Moolenaar, 2003; Luttrell, 2006). These re-
ceptors work as guanine nucleotide exchange factors (GEFs), which 
directly bind and activate the G proteins, which in turn signal via 
downstream effectors/intermediates.
Despite being distinct pathways, it has been widely demon-
strated that the RTK and GPCR/G protein pathways cross-talk 
(Liebmann and Bohmer, 2000; Lowes et al., 2002; Piiper and Zeuzem, 
2004; Natarajan and Berk, 2006). RTKs can be indirectly activated by 
GPCR/G protein intermediates by so-called transactivation (Daub 
et al., 1996; Luttrell et al., 1999; Schafer et al., 2004), and, con-
versely, G proteins may be activated downstream of RTKs (Marty 
and Ye, 2010). The concept of activation of RTKs by GPCR/G pro-
teins is widely accepted and supported by in-depth mechanistic in-
sights; however, the converse concept, that trimeric G proteins may 
be activated upon RTK stimulation, remains highly controversial be-
cause neither RTKs nor RTK-binding adaptors described to date 
possess any intrinsic GEF activity toward trimeric G proteins. The 
lack of concrete mechanistic insights into direct or indirect stimula-
tion of G proteins by RTKs has fuelled speculation (Marty and Ye, 
2010) that perhaps RTKs transactivate GPCRs through physical as-
sociation with G proteins (Sun et al., 1995; Poppleton et al., 1996), 
phosphorylation of the GPCRs, up-regulation of GPCR-ligand syn-
thesis, or various combinations of these. Despite decades of inves-
tigation yielding numerous clues that growth factors can activate 
heterotrimeric G proteins (Marty and Ye, 2010), the fundamental 
questions as to how that occurs in cells and what might be the bio-
logical significance of such activation remain unanswered.
Besides receptor GEFs, that is, GPCRs, heterotrimeric G-protein 
signaling can also be activated by nonreceptor GEFs, a rapidly 
growing family of G protein modulators (Cismowski et al., 2000, 
2001; Tall et al., 2003; Garcia-Marcos et al., 2009; Lee and Dohlman, 
2008). The Gα-interacting vesicle-associated protein (GIV, also 
known as Girdin) is a multidomain, nonreceptor GEF for G proteins, 
Gαi1/2/3 (Garcia-Marcos et al., 2009), which can enhance phospho-
inositide 3-kinase (PI3K)/Akt signals, remodel cytoskeleton, and trig-
ger cell migration downstream of multiple ligand-activated RTKs 
(Ghosh et al., 2011), for example, EGF receptor (EGFR; Enomoto 
et al., 2005; Ghosh et al., 2008, 2010), insulin-like growth factor 1 
receptor (IGF1R; Jiang et al., 2008), vascular endothelial growth fac-
tor receptor (VEGFR; Kitamura et al., 2008; Wang et al., 2014), 
platelet-derived growth factor receptor (Lopez-Sanchez et al., 2014), 
and insulin R (Garcia-Marcos et al., 2010, 2011a, 2012; Ghosh et al., 
2008; Lin et al., 2011). Consistent with its overly promiscuous behav-
ior of being able to partner with multiple receptors/pathways and 
affect multireceptor signaling, GIV plays major roles in diverse bio-
logical processes, including epithelial wound healing (Enomoto 
et al., 2005; Ghosh et al., 2008), macrophage chemotaxis (Ghosh 
et al., 2008), development (Puseenam et al., 2009; Yamaguchi et al., 
2010), autophagy (Garcia-Marcos et al., 2011a), neuronal migration 
(Enomoto et al., 2009; Porteous and Millar, 2009; Wang et al., 2011), 
podocyte survival in nephrotic syndrome (Wang et al., 2014), fibro-
sis/repair in the injured liver (Lopez-Sanchez et al., 2014), vascular 
injury and repair (Miyake et al., 2011), tumor neoangiogenesis 
(Kitamura et al., 2008), tumor cell migration (Enomoto et al., 2005; 
Jiang et al., 2008; Ghosh et al., 2010), cancer invasion (Jiang et al., 
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the critical GXFXXR motif, which is con-
served across all SH2 adaptors, widely impli-
cated in the structural basis for recognition 
and binding of the phosphotyrosine ligand 
(Schlessinger, 1994; Songyang et al., 1993, 
1994), and highly conserved in GIV (Figure 
2b). Of note, the three X residues within this 
GXFXXR motif in GIV were unusual in that 
they were GDFYDR instead of the hydro-
phobic side chains that are typically seen in 
other SH2 proteins (Supplemental Figure 
S1). A phylogenetic analysis of GIV revealed 
that this motif is conserved in mammals, 
whereas it is absent in birds, fish, or lower 
animals (Figure 2c and Supplemental Figure 
S2). Therefore the GXFXXR motif of GIV, 
which is key to the functions of the SH2-like 
domain, is evolutionarily younger than the 
GEF motif (the latter evolves earliest in fish; 
Garcia-Marcos et al., 2009) and the two criti-
cal C-terminal tyrosines that upon phospho-
rylation bind and activate PI3K (which 
evolved first in birds; Lin et al., 2011; Sup-
plemental Figure S2). Next we built a ho-
mology model of the putative SH2-like do-
main in the C-terminus of GIV using the ICM 
homology modeling procedure (Cardozo 
et al., 1995, 2000; Abagyan et al., 1997) and 
the available structures of SH2 domains 
and the GIV-SH2 sequence alignment (Sup-
plemental Figure S1; see Materials and 
Methods). The modeled structure of human 
GIV-SH2 superimposed onto the known 
structure of SOCS3 (Protein Data Bank [PDB] 
2hmh), another SH2 domain (Figure 2d), re-
vealed that the putative SH2-like domain 
has the same characteristics as all other SH2 
domains; they feature an antiparallel β-sheet 
flanked by α-helices and mostly short loops, 
and the α-helices and the edge of the β-
sheet create a fairly flat surface for phosphopeptide binding. The 
homology model also provided clues into how the SH2-like domain 
remains stably folded in the presence of phosphotyrosine ligands 
despite its unusual polar composition. For example, both Asp-1741 
and Asp-1744 within the 1740GDFYDR1745 motif are buried compen-
sated charges making multiple favorable polar interactions with the 
surrounding residue side chains in the folded state (Figure 2e). Spe-
cifically, the carboxyl group of Asp-1741 is in hydrogen-bonding 
proximity of hydroxyl groups of Tyr-1743 (also a part of 1740GD-
FYDR1745), Ser-1733, Ser-1828, and possibly the primary amine of 
Lys-1737. Similarly, Asp-1744 within the 1740GDFYDR1745 motif is 
favorably close to the side chains of Ser-1714, Arg-1790, and Ser-
1805. These findings indicate that the unusual polar residues found 
in the GXFXXR motif are stabilized in the folded (SH2-like) form and 
provide insights into the role of the unusual Tyr at 1743 within the 
1740GXFXXR1745 motif (Figure 2e).
A model of the complex between GIV’s SH2-like domain and the 
EGFR-derived phosphotyrosine peptide containing pY1148 and its 
flanking sequence revealed that the phosphotyrosine binding pocket 
of GIV’s SH2-like domain is mostly basic, which is compatible with 
binding to the acidic residues that flank Y1148 (and Y1173) of EGFR 
(Figure 2f). Because GIV’s putative SH2-like domain shares weak 
two major sites of receptor autophosphorylation on the EGFR tail is 
direct.
The C-terminus of GIV contains a unique SH2-like domain
Next we examined whether GIV-CT contains any functional domains 
that might recognize and bind the major autophosphorylation sites 
on EGFR tail—the SH2 and phosphotyrosine-binding (PTB) do-
mains, two well-characterized and widely studied domains that rec-
ognize and bind phosphotyrosines (Schlessinger and Lemmon, 
2003). To search systematically for similarities between GIV and 
other known phosphotyrosine binding domains, we aligned the se-
quences corresponding to the C-terminal domain of human 
(BAE44387; aa 1660–1870) and mouse (NP_789811; aa 1600–1845) 
GIV with other known SH2 and PTB domains in various proteins by 
pfam alignment using the MolSoft ICM molecular modeling suite 
(Abagyan et al., 1997; Cardozo et al., 1995, 2000). A stretch 
of ∼110 aa, 1713–1823, of GIV-CT showed weak similarity to the 
consensus sequence shared by 43 other SH2 domains in various 
proteins (Supplemental Figure S1), whereas no significant similarity 
was noted between known PTB domains and GIV. This putative 
SH2-like stretch in GIV’s C-terminus lies ∼15 aa downstream of the 
previously reported GEF motif (Figure 2a). This stretch contains 
FIGURE 1: The C-terminus of GIV directly binds autophosphorylated cytoplasmic tails of 
multiple RTKs. (a) Recombinant cytoplasmic tails of EGFR, InsR, and VEGFR were 
autophosphorylated and subsequently used in binding assays with His-GIV-CT (aa 1660–1870) or 
His-Sec22 (a negative control) prebound to cobalt beads. Bound proteins were analyzed for 
His-tagged proteins by Ponceau staining (bottom) and autophosphorylated receptors by IB with 
anti-pTyr mAb (top). (b) Schematic representation of GST-tagged, phospho–EGFR-tail peptides 
used in this work. (c, d) Equal aliquots (25 μg) of GST and GST-EGFR peptides containing the 
indicated tyrosines were autophosphorylated in vitro using recombinant EGFR kinase and 
subsequently used in pull-down assays with His-GIV-CT as in a. (c) An aliquot of the GST proteins 
were analyzed for GST and pTyr by IB. Single-channel images for GST and pTyr are displayed in 
grayscale. Yellow pixels in the overlay images (merge panels) confirm that Y1068, 86, Y1148, and 
Y1173 are autophosphorylated on tyrosine(s) by EGFR (lanes 2, 4, 5), whereas GST (lane 1) and 
GST-Y1114 (lane 3) are not. (d) Bound proteins were visualized by IB for His. His-GIV-CT bound 
strongly to GST-Y1148 (lane 7) and with GST-Y1173 (lane 8) but not to GST alone or other 
GST-EGFR peptides (lanes 4–6).
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FIGURE 2: GIV’s C-terminus folds into a SH2-like domain in the presence of phosphotyrosine 
ligand. (a) Schematic representation of the domain organization of GIV. The putative SH2-like 
domain (dark blue) is located in the C-terminus, ∼15 aa downstream of the GEF motif (black), within 
the Akt and actin-binding domains (light blue). Other domains include a microtubule-binding hook 
domain (red), a coiled-coil homodimerization 
domain (yellow), a Gα-binding domain (GBD, 
green), and a PI4P-binding domain (purple). 
The numbers denote the amino acids marking 
the boundaries of each domain. (b) The 
sequence corresponding to the C-terminal 
domain of human (BAE44387, aa 1623–1870) 
GIV/Girdin was used to align with 19 other 
known SH2 domains in various proteins by 
pfam alignment using the MolSoft molecular 
modeling platform. Pfam contains multiple 
alignments and hidden Markov model–based 
profiles (HMM profiles) of complete protein 
domains. The GXFXXR motif that is conserved 
among all SH2-like domains and conserved in 
GIV is highlighted (see also Supplemental 
Figure S1). (c) The sequence corresponding to 
the C-terminal domain of human GIV 
(BAE44387, aa 1623–1870) was used to 
identify homologues by BLAST search. The 
phosphotyrosine recognizing GXFXXR motif of 
GIV is absent in fish, birds, and platypus 
(egg-laying mammals) but highly conserved in 
higher mammals (see also Supplemental 
Figure S2 for an extended alignment). (d) A 
structural model of GIV’s C-terminal sequence 
(aa 1714–1815; depicted as a ribbon, colored 
blue to red from N- to C-terminus) was built 
based on the alignment with 43 known SH2 
templates using ICM software (MolSoft). 
Superimposition of the model onto an 
established SH2 domain complex structure 
(C-terminal SH2 domain of SOCS3 [black] 
bound to LR63 phosphopeptide derived [teal 
blue], PDB 2hmh) illustrates fold similarity.  
(e) Predicted atomic environment of the polar 
residues in the 1740-GDFYDR-1745 motif in 
the GIV CT in its folded SH2-like state. 
Asp1741, Tyr1743, and Asp1745 are shown in 
yellow. These residues are polar, unlike the 
corresponding residues in typical SH2 
domains. In the predicted folded SH2 state, 
residues in gray make favorable polar 
interactions (cyan) with the residues in yellow. 
(f) Molecular modeling of the interface 
between GIV’s SH2 domain and EGFR-derived 
phosphotyrosine peptide (purple) 
corresponding to pTyr1148 and its flanking 
residues, a high-affinity binding site for GIV on 
the EGF receptor. The acidic, neutral, and 
basic potentials are displayed in red, white, 
and blue, respectively. The electrostatic 
surface potential of the phosphotyrosine-
recognizing and -binding pocket of GIV’s SH2 
domain is mostly basic. (g) Equal aliquots of 
His-GIV CT were first incubated with 10-fold 
molar excess of commercially synthesized 
pY1173EGFR or dephosphorylated control 
EGFR peptides before subjecting it to limited 
tryptic proteolysis on ice. Reactions were 
analyzed for GIV-CT (His) by IB. A trypsin-
resistant product of ∼15 kDa is seen (asterisk) 
exclusively when His-GIV-CT is preincubated 
with phosphorylated EGFR peptide. Using 
His-GIV-CT-RL as substrate, it was confirmed 
that addition of pY1173EGFR peptide alone 
did not inhibit trypsin’s protease activity 
(unpublished data).
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was detected when the critical Arg within the ‘GXFXXR’ motif, which 
was indispensable for GIV to recognize and bind phosphotyrosines 
on the EGFR tail (Figure 3d), was mutated to Leu (R1745L; hence-
forth referred to as RL). Taken together, these results demonstrate 
that a functional SH2-like domain at its C-terminus is required and 
sufficient for GIV to recognize and directly bind sites of autophos-
phorylation on the EGFR tail.
GIV’s GEF and SH2-like domains cooperatively recruit 
Gαi to ligand-activated RTKs and trigger its subsequent 
activation
Next we investigated the functional relationship between GIV’s 
SH2-like domain and its previously defined GEF motif (Garcia-
Marcos et al., 2009), which binds and activates Gαi. To determine 
whether an intact GEF motif is required for GIV’s SH2 domain to 
bind phosphotyrosines, we used His-GIV-CT WT or mutant pro-
teins that are either GEF-deficient (FA) or SH2-deficient (RL) in 
binding assays with in vitro–phosphorylated, GST-tagged pY1148 
EGFR tail. We found that the WT GIV-CT and the FA mutant bound 
phosphorylated EGFR tail to an equal extent, whereas the RL mu-
tant did not (Figure 4a), indicating that in the absence of an intact 
GEF motif, GIV’s SH2-like domain is sufficient to recognize and 
bind phosphotyrosines on the EGFR tail. To whether if an intact 
SH2-like domain is required for GIV’s GEF motif to bind and acti-
vate Gαi, we used the His-GIV-CT proteins in binding assays with 
GDP-loaded GST-Gαi3 (Figure 4b) and in steady-state GTPase as-
says with His-Gαi3 (Figure 4c). We found that the WT GIV-CT and 
the RL mutant bound (Figure 4b) and activated (Figure 4c) Gαi3 to 
an equal extent, whereas the FA mutant did not, demonstrating 
that the SH2-like domain is not required for GIV to bind and acti-
vate Gαi3. To determine the contribution of GIV’s SH2-like domain 
and its GEF motif in the formation of Gαi-GIV-EGFR ternary com-
plexes, we carried out binding assays with three recombinant 
proteins—His-Gαi3, His-GIV-CT, and in vitro–phosphorylated GST-
pY1148 EGFR tail. We found that Gαi3 bound phosphorylated 
EGFR tail exclusively in the presence of WT GIV-CT (Figure 4d), 
indicating that the Gαi3-EGFR interaction is indirect and requires 
GIV-CT. This interaction was abolished when the WT GIV-CT pro-
tein was replaced by either the SH2-deficient or the GEF-deficient 
mutant (Figure 4d), indicating that both the SH2-like domain and 
the GEF motif are required for GIV to facilitate the interaction be-
tween Gαi3 and EGFR and to trigger the assembly of Gαi3-GIV-
EGFR ternary complexes in vitro.
Next we asked whether GIV’s SH2-like domain is required for 
the recruitment of Gαi3 to ligand-activated EGFR. To this end, 
we analyzed receptor-bound immune complexes (Figure 4e) be-
fore and after ligand stimulation in GIV-depleted HeLa cells sta-
bly expressing small interfering RNA (siRNA)–resistant, FLAG-
tagged WT and mutant GIV (Supplemental Figure S3, A and B). 
As shown previously (Ghosh et al., 2010), Gαi3 coimmunopre-
cipitated with EGFR exclusively after ligand stimulation in HeLa 
GIV-WT cells but not in HeLa GIV-FA cells, which express GEF-
deficient GIV mutant (Figure 4e). Gαi3 was also undetectable in 
EGFR-bound complexes immunoprecipitated from HeLa GIV-RL 
cells, which express SH2-deficient GIV mutant, indicating that re-
cruitment of Gαi3 to ligand-activated EGFR requires both the 
SH2-like domain and GEF motif in GIV to remain intact. We found 
that recruitment of Gαi3 to other RTKs—for example, ligand-ac-
tivated InsR—also requires an intact SH2-like domain in GIV, be-
cause Gαi3 coimmunoprecipitated with InsR exclusively after li-
gand stimulation in HeLa GIV-WT but not in HeLa GIV-RL cells 
(Supplemental Figure S4).
sequence similarity with other SH2 proteins with an unusually polar 
composition and multiple strategies for expression and purification 
of GIV’s ∼110-aa-long SH2-like domain from bacteria failed, we 
asked whether GIV’s SH2-like domain represents a transient state 
that folds only in the presence of ligand (phosphotyrosines on RTK 
tail) but remains unstructured or poorly structured in physiology. We 
explored this possibility using limited proteolysis, a simple biochem-
ical method that can reveal large changes in protein conformation. 
When we incubated purified histidine (His)-GIV-CT with phosphory-
lated or dephosphorylated Y1173EGFR peptides and subsequently 
carried out limited proteolysis with trypsin, we found that His-GIV-CT 
was highly susceptible to proteolysis when preincubated with de-
phosphorylated Y1173EGFR peptide but relatively resistant to 
proteolysis when preincubated with phosphorylated Y1173EGFR 
peptide, a natural ligand for GIV’s SH2-like domain (Figure 2g). These 
results are consistent with the possibility that GIV’s C-terminus folds 
into trypsin-resistant conformation exclusively in the presence of pY 
ligand. These findings, together with the fact that most sequence 
analysis programs predicted this region to be poorly structured, 
likely due to the unusual abundance of polar residues, suggest that 
this region of GIV-CT may have properties of structural plasticity be-
tween an intrinsically disordered state during quiescence and a 
folded SH2-like modular state when engaged with multiple RTKs.
GIV’s SH2-like domain is required and sufficient to 
recognize and bind ligand-activated RTKs
To determine whether GIV-CT folds into a SH2-like module and rec-
ognizes/binds to phosphotyrosine ligands, as predicted by the ho-
mology model in Figure 2, we made a number of predictions by 
computational modeling regarding the effect of strategically placed 
mutations within GIV’s SH2-like domain (Figure 3, a and b): 1) muta-
tions in the core GXFXXR motif and phosphotyrosine binding pocket 
that were predicted to abolish the GIV:EGFR interaction, 2) muta-
tions within adjacent sequences that do not participate in phospho-
tyrosine recognition and were predicted to be inconsequential, and 
3) a mutation within the pocket that was expected to favor binding. 
We found all these predictions to be accurate when we carried out 
binding assays using various His-tagged GIV mutants and in vitro–
phosphorylated, GST-tagged pY1148 EGFR tail peptide (Figure 3, c 
and d); that is, compared with GIV–wild type (WT), some mutants 
abolished binding (lanes 2, 4–6, and 8), whereas others bound 
equally well (lanes 3, 9, and 10) or consistently better (F1765T; 
∼1.45-fold, p < 0.01). These findings validate our homology model 
of GIV-SH2 (Figure 2, d and f) and demonstrate that the conserved 
‘GXFXXR’ core motif and the flanking sequence that the C-terminus 
of GIV shares with other SH2 adaptors can function as a SH2-like 
domain, in that they recognize and directly bind phosphotyrosine 
ligands. These results also indicate that the ∼100- to 110-aa stretch 
within GIV’s C-terminus is likely to assume a SH2-like domain struc-
ture as predicted by homology modeling (Figure 2).
Next we asked whether the isolated SH2-like domain is sufficient 
for GIV to bind EGFR in cells. We used a bimolecular fluorescence 
complementation (BiFC) approach, in which interaction between 
two proteins, each tagged with the N- or C-terminus of Venus–
yellow fluorescent protein (YFP; VN or VC), is assessed by the abun-
dance and distribution of fluorescence emitted by a functionally 
folded Venus-YFP protein only when the two proteins are within 
10 nm of each other for a significant duration of time (Shyu et al., 
2008). We found that cells coexpressing EGFR-VC and a WT VN-
GIV-SH2-like domain (aa 1714–1815; Figure 3. e and f) display 
yellow fluorescence at the plasma membrane (PM) and on vesicular 
structures, presumably endosomes (Figure 3f). No such fluorescence 
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Next we asked whether GIV-dependent 
recruitment of Gαi to ligand-activated RTKs 
affects G protein activation downstream of 
ligand-activated receptors. When we car-
ried out immunoprecipitation assays with 
an antibody that has been characterized 
extensively (lane et al., 2008) and specifi-
cally recognizes the active conformation of 
GTP-bound Gαi (Supplemental Figure S5), 
we found that Gαi was activated in HeLa-
GIV WT exclusively after EGF stimulation 
but not in HeLa GIV-RL, indicating that 
GIV’s SH2 domain is required for Gαi acti-
vation downstream of EGFR (Figure 4f). 
Consistent with differential activation of 
Gαi in the two cell lines, cellular cyclical 
AMP (cAMP), a second messenger pro-
duced by adenylyl cyclase, was elevated 
(Figure 4g), and phosphorylation of cAMP 
response element–binding protein (CREB) 
was enhanced in GIV-RL cells compared 
with GIV-WT cells (Figure 4h). Taken to-
gether, these findings demonstrate 1) that 
the two functional modules of GIV, the 
SH2-like domain and the GEF motif, func-
tion independent of each other in the con-
text of receptor recognition and enzyme 
(GEF) activity, respectively, but 2) they co-
operate to form the RTK-GIV-Gαi ternary 
complexes (in vitro and in cells) and acti-
vate Gαi downstream of growth factor 
receptors.
FIGURE 3: Validation of the homology model of GIV’s SH2 domain. (a, b) Based on the 
generated three-dimensional model shown in Figure 2, d and e, a series of GIV C-terminal 
mutations were predicted to decrease, increase, or have no effect on the recognition and 
binding to the phosphotyrosine 1148 on the cytoplasmic tail of EGFR. These residues are 
highlighted in red, green, and gold, and listed along with the preferred amino acid substitution 
in b. R1745 of GIV corresponds to the invariant Arg residue at the βB5 position within the 
conserved GXFXXR motif that is characteristic of the entire SH2 family of adaptors (Songyang 
et al., 1993, 1994; Schlessinger, 1994). The βC-βD loop, which is predicted to not affect 
phosphotyrosine binding, was either deleted or replaced with a neutral flexible linker, SGS. 
F1765 was mutated to Thr (T) to resemble the mouse sequence; this substitution is predicted 
to increase the depth of the binding pocket and improve binding. α, helix; β, β-sheets. 
(c, d) Equal aliquots (25 μg) of GST and 
GST-pY1148 were phosphorylated in vitro 
using recombinant EGFR kinase and used in 
pull-down assays with purified WT or various 
mutants of His-GIV-CT listed in b. (c) An 
aliquot of the GST proteins was analyzed for 
GST and pTyr by IB. Yellow pixels in the 
overlay images (merge panels) confirm that 
GST-pY1148 is autophosphorylated on 
tyrosine(s) by EGFR kinase in vitro. (d) Bound 
GIV CT was visualized by IB for His. Equal 
loading of GST and GST-pY1148 was 
confirmed by Ponceau S staining. A 
representative experiment is shown; n = 4. 
(e) Schematic representation of EGFR-VC 
and VN-GIV-SH2 constructs used for BiFC 
assay. (f) Cos7 cells were cotransfected with 
indicated complementary pairs of probes, 
grown in 10% FBS, fixed, and analyzed for 
fluorescence by confocal microscopy. Images 
representative of each condition are shown. 
Fluorescence is observed at the PM 
(arrowheads) and on vesicles (arrows; likely 
endolysosomal compartments) exclusively 
when complementary VN-GIV-SH2 WT, but 
not the SH2-deficient RL mutant probe, was 
cotransfected with EGFR-VC. Paired 
transfection of other complementary VN- 
and VC-control probes did not show 
discernible fluorescence (∼400 cells/
experiment; n = 4).
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WT. The FA (lane 6) but not RL (lane 7) 
mutant of GIV-CT binds GST-pY EGFR-T.  
(b) WT, FA, and RL mutants of His-GIV-CT 
were incubated with 5 μg of GST-Gαi3 or 
GST preloaded with GDP immobilized on 
glutathione beads. Bound proteins were 
analyzed by IB for GIV-CT using anti-His 
mAb. His-GIV-CT WT (lane 3) and RL mutant 
(lane 9) bound GST-Gαi3 equally, and, as 
anticipated, the FA mutant did not (lane 6). 
(c) The amount of GTP hydrolyzed in 10 min 
by His-Gαi3 was determined in the 
presence of the indicated amounts of WT 
(∆), FA (∆), and RL mutant (•) His-GIV-CT. 
Both WT and RL mutants increased the 
steady-state GTPase activity of His-Gαi3 
efficiently and equally in a dose-dependent 
manner, whereas the FA mutant did not. 
The basal steady-state GTPase activity of 
His-Gαi3 is 0.021 ± 0.04 mol Pi mol Gαi3−1 
min−1 and the results are displayed as 
percentage of basal activity. (d) Equal 
aliquots (15 μg) of GST-EGFR-T (aa 
1064–1210) were either phosphorylated in 
vitro with recombinant EGFR kinase 
(GST-pY EGFR-T; lanes 2 and 4–7) or mock 
treated (GST-EGFR-T; lanes 1 and 3) and 
subsequently used in pull-down assays with 
purified His-Gαi3 alone (lanes 1 and 2), 
His-GIV-CT alone (lanes 3 and 4), or a mix of 
His-Gαi3 and WT, FA, or RL mutants of 
His-GIV-CT as indicated. Bound proteins 
were analyzed for His-GIV-CT and 
phosphorylation of GST-EGFR-T by IB. Gαi3 
binds GST-pY EGFR in the presence of WT 
(lane 5) but not FA (lane 6) or RL (lane 7). 
(e) HeLa GIV-WT, HeLa GIV-FA, and HeLa 
GIV-RL cells stably expressing the indicated 
siRNA-resistant GIV constructs were 
depleted of endogenous GIV by siRNA, 
serum starved for 16 h, and then stimulated 
with EGF for the indicated durations before 
lysis. Equal aliquots of lysates (bottom) 
were incubated with anti-EGFR mAb (#225 
IgG). Immune complexes (top) were 
analyzed for total (t-EGFR) and Gαi3 by IB. 
(f) Equal aliquots of lysates (bottom) from 
starved or EGF-treated HeLa GIV-WT and 
GIV-RL cells were incubated with anti-
Gαi:GTP mAb. Immune complexes (top) 
were analyzed for Gαi3 by IB. (g) HeLa-GIV-
WT and GIV-RL cells were depleted of 
endogenous GIV as in e, serum starved 
(0.2% FBS), and subsequently stimulated 
with EGF and analyzed for cAMP by RIA 
(see Materials and Methods). Results are 
displayed as fold change in cAMP (y-axis) in 
each cell line normalized to their respective 
starved state. (h) HeLa-GIV-WT and GIV-RL 
cells were stimulated with EGF before lysis 
as in e. Top, equal aliquots of whole-cell 
lysates were analyzed for phosphorylated 
CREB (pCREB) and tubulin by IB. Bottom, 
bar graphs display the quantification of 
pCREB/tubulin by band densitometry. All 
values are normalized to the starved 
HeLa-GIV-WT cells. Results are shown as 
mean ± SEM; n = 3.
FIGURE 4: GIV’s SH2 and GEF domains are required for the recruitment of Gαi3 to ligand-
activated EGFR and activation of G protein after EGF stimulation. (a) Equal aliquots (15 μg) 
of GST-EGFR-T (aa 1064–1210) were either phosphorylated in vitro using 5 ng of 
recombinant EGFR kinase (GST-pY EGFR-T; lanes 5–7) or mock treated (GST-EGFR-T; lane 4) 
and subsequently used in pull-down assays with equal amounts of purified WT, FA (GEF-
deficient), or RL (SH2-deficient) mutants of His-GIV-CT (aa 1660–1870; lanes 1–3, inputs). 
Bound proteins were analyzed for His-GIV-CT and phosphorylation of GST-EGFR-T by IB. As 
anticipated, GST-pY EGFR-T (lane 5) but not GST-EGFR-T (lane 4) directly binds His-GIV-CT 
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directly bind pY1148 and 1173 on EGFR tail, the newly identified 
SH2-like domain in GIV may shape EGF signaling by affecting the 
profile of SH2 adaptor recruitment to the ligand-activated receptor 
tail. We focused on Shc1 and SHP1, two SH2 adaptors that are ma-
jor players in shaping EGF signaling (Keilhack et al., 1998; Sakaguchi 
et al., 1998), because they bind EGFR predominantly at the se-
quences flanking pY1148 and pY1173: Shc1 binds primarily to 
pY1148 and weakly to pY1173 (Okabayashi et al., 1994), whereas 
SHP1 binds primarily to pY1173 and weakly to pY1148 (Keilhack 
et al., 1998). In GST pull-down assays with immobilized phosphory-
lated GST-EGFR tail pY1173 peptide, increasing amounts of His-
SHP-1, and constant amounts of His-tagged GIV-CT proteins in so-
lution, we found that increased binding of SHP1 coincided with 
decreased binding of GIV-CT to EGFR phosphopeptide (Figure 6a), 
indicating that SHP1 and GIV-CT compete for pY1173 on EGFR tail. 
Similarly, in GST pull-down assays with immobilized phosphorylated 
GST-EGFR tail pY1148 peptide, increasing amounts of His-tagged 
GIV-CT, and constant amounts of Shc1 proteins in solution, we 
found that increased binding of GIV coincided with decreased bind-
ing of Shc1 to EGFR phosphopeptide (Figure 6b), indicating that 
Shc1 and GIV-CT compete for pY1148 on EGFR tail. To determine 
whether such competition occurs in cells, we evaluated the profile 
of SH2-adaptor recruitment to the EGFR tail in GIV-WT versus GIV-
RL HeLa cells by immunoprecipitating the receptor and analyzing 
the receptor-bound complexes by immunoblotting (IB). We found 
that the profile of adaptor recruitment was significantly different in 
the two cell lines. GIV was recruited to ligand-activated EGFR in 
GIV-WT but not in GIV-RL cells (Figure 6c). When GIV failed to be 
recruited to EGFR in GIV-RL cells, recruitment of p85α (PI3K) and 
Grb2 was also suppressed but recruitment of SHP1 and Shc1 was 
enhanced. Consistent with the enhanced recruitment of SHP1, in 
GIV-RL cells, we observe that activation of SHP1, as determined by 
the abundance of pY536SHP1 (Figure 6c, Lysates), and dephospho-
rylation of key autophosphorylation sites in EGFR (Figure 6c, Immu-
noprecipitates) were enhanced. Together these results demonstrate 
that binding of GIV-SH2 competes with SHP1 and Shc1 for binding 
to two major sites of autophosphorylation on EGFR.
We also found that presence or absence of an intact SH2 domain 
in GIV is a key determinant of how two major downstream pathways 
are modulated (Figure 6d): in GIV-RL cells, activation of the PI3K/Akt 
pathway, as determined by Akt phosphorylation, was suppressed, 
whereas activation of the MAPK/ERK pathway, as determined by 
ERK phosphorylation, was enhanced compared with GIV-WT cells. 
Together these results demonstrate that the GIV-SH2 domain af-
fects the earliest events in EGF signaling—SH2-adaptor recruitment 
and the pattern of receptor autophosphorylation—by competing 
with key adaptors that shape major downstream signaling 
pathways.
On the basis of our results so far, we propose the following model 
(Figure 6e). In cells with little or no GIV expression or in those ex-
pressing GIV mutants/isoforms lacking the C-terminus or a func-
tional SH2-like domain, ligand-activated EGFR triggers unopposed 
recruitment of Shc1 and SHP-1 adaptors, which in turn ensures 
enhancement of the MAPK/ERK pathway by Shc1 and rapid recep-
tor dephosphorylation by SHP-1. In cells expressing high copies of 
functionally intact GIV, GIV-SH2 competes with both Shc1 and SHP-1 
for binding sites on EGFR tail. Recruitment of GIV’s SH2-like domain 
to EGFR suppresses/terminates Shc1-mediated MAPK/ERK activa-
tion and antagonizes SHP-1–mediated receptor dephosphorylation 
while simultaneously triggering two other pathways in parallel— 
1) GIV’s GEF function links G protein activation to ligand-activated 
receptor, and 2) EGFR phosphorylates GIV on tyrosines that help 
GIV-SH2 domain is required for tyrosine phosphorylation 
of GIV by RTKs
We previously demonstrated that upon ligand stimulation, multiple 
RTKs phosphorylate GIV at two critical tyrosines, Y1764 and Y1798, 
and that both sites are capable of binding and activating class 1A 
PI3Ks (Lin et al., 2011). Although these two tyrosines are located 
within the boundaries of the SH2-like domain of GIV (Figure 5a and 
Supplemental Figure S6a), the homology model predicts that they 
are exposed and accessible to RTKs (Figure 5a). We asked whether 
receptor-mediated phosphorylation of GIV in cells requires an intact 
SH2-like domain of GIV, thereby bringing the substrate (GIV) in prox-
imity to the kinase (EGFR). To answer this, we compared the extent 
of EGF-stimulated tyrosine phosphorylation of wild-type GIV to the 
SH2-deficient RL mutant and a previously described phosphoryla-
tion-deficient GIV-YF mutant (Lin et al., 2011); the latter is a negative 
control in which both tyrosines were replaced by Phe (F). Because 
nonreceptor TKs of the Src family can also phosphorylate GIV on 
those two tyrosines (Lin et al., 2011), we used the kinase inhibitor 
PP2 to abolish any contribution to GIV phosphorylation via the Src 
family of kinases, exactly as we used previously (Lin et al., 2011; 
Mittal et al., 2011). On EGF stimulation, wild-type GIV, but not the 
RL and the YF mutants, was tyrosine phosphorylated (Figure 5b), 
indicating that an intact SH2-like domain is essential for enhanced 
tyrosine phosphorylation in GIV. Because EGFR kinase phosphory-
lated the RL mutant just as efficiently as WT GIV-CT in vitro 
(Supplemental Figure S6b), its failure to be phosphorylated in cells 
(Figure 5b) indicates that the SH2-like function of GIV is required for 
enhanced phosphorylation of GIV by EGFR in cells.
Because protein phosphorylation predominantly occurs within 
intrinsically disordered regions of substrate proteins (Iakoucheva 
et al., 2004) and the two tyrosines of GIV are abundantly phospho-
rylated despite being located within a SH2-like folded region, we 
asked whether RTKs phosphorylate GIV when it is intrinsically disor-
dered before folding into a SH2-like domain. We found that this is 
indeed the case, because recombinant EGFR failed to phosphory-
late His-GIV-CT when it was preincubated with its pY1173EGFR li-
gand (bound/folded in a trypsin-resistant conformation as in Figure 
2h) but robustly phosphorylated it when incubated with the dephos-
phorylated control peptide (Figure 5c). These results indicate that 
phosphorylation of GIV-CT must proceed before it completes fold-
ing into a stable SH2-like domain. We also found that both ligand-
stimulated EGFR (Figure 5d) and InsR (Figure 5e) coimmunoprecipi-
tate with pY1764GIV, indicating that tyrosine phosphorylated GIV’s 
SH2-like domain is capable of stably binding RTKs. Taken together, 
these results indicate that the dynamic interplay of RTKs with GIV is 
comprises two events that closely follow each other: 1) recognition 
of autophosphorylated RTK tail by GIV-CT via a SH2-like mechanism 
is essential for RTKs to efficiently phosphorylate GIV, and such phos-
phorylation occurs when GIV-CT is still in a partially disordered state; 
and 2) completion of folding of phosphorylated GIV-CT into a SH2-
like module, which allows tyrosine-phosphorylated GIV to be stably 
recruited to ligand-activated RTKs.
GIV-SH2 modulates EGFR signaling by regulating adaptor 
recruitment to activated receptor
We previously demonstrated (Ghosh et al., 2010) that GIV enhances 
receptor autophosphorylation, affects the recruitment of key signal-
ing adaptors to the receptor tail, and alters several major EGF sig-
naling pathways such that they are either selectively amplified (e.g., 
PI3K/Akt) or attenuated (e.g., mitogen-activated protein kinase/
extracellular signal-regulated kinase [MAPK/ERK]) via poorly under-
stood mechanisms. We reasoned that by virtue of its ability to 
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FIGURE 5: The SH2-like domain of GIV is required for enhanced tyrosine phosphorylation of GIV and subsequent 
binding to RTKs. (a) Homology model of GIV’s SH2 domain is depicted as a ribbon as in Figure 2d. The positions and the 
orientations of the two tyrosines are displayed in two views: from the “front” (pTyr-binding interface) and “back.” Both 
tyrosines are well exposed to solvent, consistent with the fact that multiple receptor and nonreceptor tyrosine kinases 
can readily access and phosphorylate them and that they can directly bind and activate PI3K (Lin et al., 2011). (b) Cos7 
cells expressing FLAG-tagged wild-type GIV (GIV-WT FLAG), SH2-deficient R1745L mutant GIV (GIV-RL FLAG), a 
tyrosine phosphorylation–deficient mutant (GIV-YF FLAG; Lin et al., 2011), or vector alone were serum starved, 
pretreated with Src inhibitor (PP2), and subsequently stimulated with EGF before lysis. GIV was immunoprecipitated 
from equal aliquots of lysates (right) with FLAG mAb, and immunoprecipitates (left) were analyzed for GIV (red) and pTyr 
(green) by IB and dual-color imaging. The merge confirms that tyrosine-phosphorylated GIV (yellow) was 
immunoprecipitated exclusively from EGF-treated cells expressing GIV-WT (lane 3) but not from cells expressing GIV-RL 
(lane 4). As shown previously (Lin et al., 2011), the negative control GIV-YF was not phosphorylated (lane 5). The lysates 
(right) were analyzed for FLAG (GIV-FLAG), phospho-Akt (pAkt), and tubulin by IB. (c) Equal aliquots of His-GIV-CT 
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gence of two pathways on a common GIV platform. We provide evi-
dence demonstrating how these two domains cooperatively assem-
ble RTK (activated)-GIV-Gαi ternary complexes in vitro and in cells. 
When GIV is uncoupled from EGFR (i.e., in cells expressing SH2-
deficient GIV mutants), both recruitment of Gαi to the ligand-acti-
vated receptor and subsequent activation of the G protein in re-
sponse to EGF are abolished. Therefore our discovery of a SH2-like 
domain in GIV explains how RTKs trigger activation of Gi proteins 
and sheds light on the long-standing questions surrounding RTK/G 
protein cross-talk.
The significance of our findings also lies in the fact that none of 
the other >100 SH2 adaptors that were identified before GIV (Liu 
et al. 2011) possesses intrinsic GEF activity toward trimeric G pro-
teins or, for that matter, ability to either bind or modulate any 
other aspect of trimeric G protein signaling. Similarly, GIV is a rare 
example within a growing family of nonreceptor modulators of G 
proteins (GEFs, GTPase-activating proteins, and GDP dissociation 
inhibitors; Siderovski and Willard, 2005) with a structural module 
that recognizes and binds ligand-activated RTKs. Moreover, the 
discovery of a SH2-like domain within GIV’s C-terminus as the 
structural basis for how GIV binds ligand-activated, autophospho-
rylated RTKs provides mechanistic insights into our observation 
that GIV activates Gαi downstream of multiple growth factors dur-
ing a variety of cellular processes (Garcia-Marcos et al., 2009, 
2011a; Ghosh et al., 2010; Lopez-Sanchez et al., 2014; Wang 
et al., 2014). We conclude that the unique combination of GEF 
and SH2 domains in GIV constitutes a novel platform for cross-talk 
that relays signals from ligand-activated growth factor RTKs to Gi 
proteins.
Furthermore, we demonstrate that GIV’s C-terminal ∼100-aa 
stretch that folds into a SH2-like domain is intrinsically disordered or 
partially structured in the resting state. Folding into a trypsin-resis-
tant stable structure occurs when autophosphorylated tyrosines on 
cytoplasmic tails of RTKs are available, which are the natural ligand 
for GIV’s SH2-like domain. In that way, GIV joins the rank of numer-
ous examples of eukaryotic proteins that are intrinsically disordered 
or partially structured under physiological conditions and fold into 
functional modules, especially in the context of signal transduction 
(Iakoucheva et al., 2002; Dyson and Wright, 2002, 2005; Dunker 
et al., 2008). Such proteins, while structurally poor, are functionally 
rich by virtue of the flexibility of their modular structures. We con-
clude that much like those intrinsically disordered proteins, GIV’s 
SH2-like folded structure is induced upon binding to its biological 
target, that is, activated RTKs. Evolution of such structural plasticity 
in GIV is likely to assemble distinct interactomes in the disordered 
versus SH2-folded states, thereby contributing to functional enrich-
ment. Because GIV’s C-terminus is enriched in Ser/Thr residues, 
some of which are heavily phosphorylated (www.phosphosite.org), 
it is possible that additional phosphoevents on GIV’s C-terminus 
trigger and/or regulate folding of GIV’s SH2-like domain and binding 
to RTKs.
recruit and activate PI3K, thereby triggering the activation of Akt 
kinase.
GIV-SH2 regulates EGFR trafficking, degradation, actin 
remodeling, and cell migration
We previously demonstrated (Ghosh et al., 2010) that GIV induces 
rapid degradation of EGFR after receptor endocytosis, thereby re-
ducing the duration of signaling from endosomes. Because the 
SH2-like domain of GIV alters key early events in EGF signaling, we 
reasoned that it might also be responsible for altering the rate of 
receptor degradation. When we investigated this in HeLa-GIV-WT, 
-FA, and -RL cells by immunofluorescence (Figure 7a) and immuno-
blotting (Figure 7b), both approaches showed that rates of recep-
tor degradation were faster in GIV-WT cells but slower in GIV-RL 
cells, with significant amounts of receptor lingering at 30 and 60 
min (Figure 7, a and b) within EEA1-positive endocytic compart-
ments (Figure 7a). Consistent with our prior work, the rate of re-
ceptor degradation was delayed also in GIV-FA cells. Because 
both GIV-RL and GIV-FA are deficient in assembling ternary RTK-
GIV-Gαi complexes, these results indicate that both SH2 and GEF 
domains, which cooperatively assemble such ternary complexes 
(Figure 4), are required for efficient down-regulation of activated 
receptor in endocytic compartments.
Finally, we asked whether the two previously identified major 
downstream phenotypes attributed to GIV (Enomoto et al., 2005; 
Ghosh et al., 2011)—actin remodeling and cell migration—were 
affected in the absence of an intact SH2-like domain in GIV. We 
found that indeed such was the case, because GIV-RL cells, in 
which GIV is functionally uncoupled from ligand-activated EGFR, 
formation of actin stress fibers, and efficient two-dimensional cell 
migration in scratch-wound assays, were impaired (Figure 7, d and 
e). Taken together, these results demonstrate that the SH2-like 
domain described here is a critical domain that links RTKs like 
EGFR to signal transduction and modulation of cellular pheno-
type via GIV.
DISCUSSION
GIV is a unique SH2-like adaptor and imparts GEF activity 
for trimeric G proteins to RTKs
The major finding in this work is the discovery that GIV, a previously 
described nonreceptor GEF for Gαi, is a novel SH2-like adaptor that 
links multiple ligand activated RTKs—for example, EGFR and InsR to 
activation of trimeric Gi proteins. We previously demonstrated that 
the GEF domain of GIV is required for assembly of GIV:Gαi signaling 
interface, which activates Gαi (Garcia-Marcos et al., 2009). Here we 
show that adjacent to the GEF motif is a stretch of ∼110 aa within 
GIV’s C-terminus that recognizes autophosphorylated tyrosines on 
cytoplasmic tails of ligand-activated RTKs and stably folds into a 
SH2-like module to assemble the RTK:GIV signaling interface. It is 
this coexistence of G protein–activating GEF and RTK-binding SH2 
modules in tandem within GIV’s C-terminus that allows for conver-
proteins were first incubated with 10-fold molar excess of either phosphorylated (left lane) or unphosphorylated (right 
lane) EGFR tail peptides (sequence flanking Y1173) before in vitro kinase assays with recombinant EGFR kinase. GIV-CT 
is phosphorylated only in the presence of dephosphorylated EGFR peptide (which it cannot bind) but not in the 
presence of phospho-EGFR ligand. (d) EGFR was immunoprecipitated from lysates of HeLa cells starved and stimulated 
with EGF with anti-EGFR (528) mAb or control IgG. Immune complexes were analyzed for the presence of tyrosine-
phosphorylated GIV using anti-pY1764GIV and ligand-activated EGFR (pY1173 EGFR) by IB. (e) InsR was 
immunoprecipitated from lysates of Cos7 cells starved and stimulated with insulin with anti-pYInsR mAb. Immune 
complexes were analyzed for the presence of tyrosine phosphorylated GIV using anti-pY1764GIV and ligand-activated 
InsR (pYInsR) by IB.
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Recruitment of GIV to EGFR is required for enhancement of the 1) 
PI3K/Akt signaling pathway after EGF stimulation. We previously 
showed that EGFR and other RTKs phosphorylate GIV on two 
tyrosines that directly bind and activate PI3K within RTK-GIV-PI3K 
complexes at the PM (Lin et al., 2011), thereby serving as a bona 
GIV’s SH2-like domain affects key events in EGFR activation 
and downstream signaling
We also demonstrate that besides linking Gi activation to RTKs, 
GIV’s SH2-like domain has at least three other direct effects on 
growth factor signaling:
FIGURE 6: Interaction of GIV with EGFR determines the profile of other SH2 adaptors recruited to the ligand-activated 
receptor. (a) Equal aliquots (25 μg) of GST and GST-EGFR peptide containing Y1173 were autophosphorylated in vitro 
using recombinant EGFR kinase as in Figure 1c and subsequently used in pull-down assays with q constant amount 
(6 μg) of His-GIV-CT and increasing amounts of His-SHP-1 as indicated. Bound proteins were analyzed for His-SHP1 
and His-GIV-CT by IB with His. (b) Equal aliquots (25 μg) of GST and GST-EGFR peptide containing Y1148 were 
autophosphorylated in vitro using recombinant EGFR kinase as in Figure 1c and subsequently used in pull-down assays 
with a constant amount (2 μg) of His-Shc1 and increasing amounts of His-GIV-CT as indicated. Bound proteins were 
analyzed for His-Shc1 and His-GIV-CT by IB with His. (c) HeLa GIV-WT and HeLa GIV-RL cells were depleted of 
endogenous GIV, starved, and stimulated with EGF as in Figure 4e before lysis. EGFR was immunoprecipitated from 
these lysates as in Figure 5d. Immunoprecipitates (left) and lysates (right) were analyzed for receptor phosphorylation 
and various SH2 adaptors by IB. Compared to HeLa GIV-WT cells, in HeLa GIV-RL cells, recruitment of SHP1 and Shc1 to 
ligand-activated EGFR is enhanced, autophosphorylation of EGFR is reduced, and recruitment of p85α (PI3K) and Grb2 
is suppressed. (d) HeLa GIV-WT and HeLa GIV-RL cells were depleted of endogenous GIV, starved, and stimulated with 
EGF as in Figure 4e before lysis. Equal aliquots of whole-cell lysates were analyzed for phospho-Akt (pAkt), ERK 
(pERK1/2), and tubulin by IB. (e) Working model. A schematic summarizing the sequence of events triggered by the 
binding of GIV’s SH2-like domain to EGFR. Left, in the absence of GIV, upon ligand stimulation, EGFR 
autophosphorylation is triggered at Y1148 and Y1173, which serve as sites of adaptor recruitment for Shc and SHP-1, 
respectively. Shc triggers activation of the MAPK/ERK pathway, and activated SHP-1 dephosphorylates EGFR and 
down-regulates receptor signaling. Right, in the presence of GIV, EGFR autophosphorylation sites pY1148 and pY1173 
are recognized and approached by a partially structured SH2-like domain in GIV’s C-terminus. Close proximity to EGFR 
facilitates efficient phosphorylation of GIV on critical tyrosines within a partially structured SH2 domain before/
simultaneously with folding into a SH2-like module that stably docks onto autophosphorylated EGFR tail. Such docking 
competes with Shc for Y1148 and with SHP-1 for Y1173, thereby displacing and antagonizing signaling via both 
adaptors. Once GIV-SH2 is recruited to activated EGFR, GIV triggers two parallel pathways that were previously shown 
to synergistically activate Akt: a) GIV’s phosphotyrosines bind p85α (class Ia PI3K) and activate PI3K/Akt signaling (Lin 
et al., 2011), and b) GIV’s GEF motif activates Gαi in close proximity to activated EGFR and releases “free” Gβϒ, which 
directly binds p110 (class 1b PI3K) and activates PI3K/Akt signaling (Garcia-Marcos et al., 2009).
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FIGURE 7: EGFR degradation is delayed and actin remodeling and cell migration are impaired 
in the absence of an intact SH2 domain in GIV. (a) HeLa control, HeLa GIV-WT, HeLa GIV-RL, and 
HeLa GIV-FA cells stably expressing siRNA-resistant GIV constructs were either treated with 
control (Scr) siRNA or GIV siRNA, starved, and stimulated with EGF as in Figure 4e before 
fixation. Cells were costained for EEA1 (green), tEGFR (red; anti-EGFR cytoplasmic tail), and the 
nucleus/DAPI (blue). At 60 min after ligand stimulation, EGFR is virtually undetectable in GIV-WT 
cells (e, j), but significant staining is seen in GIV-RL cells (t) compared with controls (e). Images 
are representative of four independent repeats. Bar, 10 μm. (b) Serum-starved control, GIV-WT, 
GIV-RL, and GIV-FA HeLa cells were stimulated with EGF as in a before lysis. Equal aliquots of 
lysates were analyzed for total EGFR (tEGFR, anti-EGFR cytoplasmic tail) and tubulin by 
immunoblotting. (c) The amount of tEGFR present at 30 min in b was quantified by Odyssey 
infrared imaging, normalized to tubulin, and expressed as percentage remaining compared with 
0 min. Results are shown as mean ± SEM (n = 4). (d) Control HeLa cells or HeLa GIV-WT, GIV-FA, 
and GIV-RL cells expressing various siRNA-resistant GIV constructs were treated with scrambled 
fide enhancer of PI3K activity (Garcia-
Marcos et al., 2009; Lin et al., 2011). Here 
we provide evidence that phosphoryla-
tion of GIV’s C-terminal tyrosines by RTKs 
occurs when GIV exists in an intrinsically 
disordered state, because this phospho-
event is inhibited once GIV is bound to its 
pTyr ligand and stably folded into a SH2-
like module. We also show that upon 
phosphorylation, GIV folds/binds to li-
gand-activated RTKs. In cells expressing 
SH2-deficient GIV mutants, for which GIV 
is uncoupled from EGFR, tyrosine phos-
phorylation of GIV by EGFR is suppressed, 
recruitment of PI3K to EGFR-GIV com-
plexes is decreased, and subsequent ac-
tivation of downstream Akt kinase is di-
minished. On the basis of these findings, 
we propose that ligand-activated RTKs 
simultaneously induce two modifications 
on GIV: a) they trigger folding of an intrin-
sically disordered GIV C-terminus into a 
SH2-like domain, and b) they directly 
phosphorylate GIV’s tyrosines. Our results 
indicate that initiation of folding and ty-
rosine phosphorylation must coincide, 
followed by completion of folding into a 
SH2-like domain that stably docks onto 
cytoplasmic tails of activated RTKs. Re-
cruitment of tyrosine-phosphorylated 
GIV-SH2 to EGFR helps recruit and acti-
vate PI3K to initiate the previously de-
fined ‘RTK-GIV-PI3K’ axis of signaling (Lin 
et al., 2011).
2) We also demonstrate that recruitment of 
GIV to EGFR is required for suppression 
of the MAPK/ERK signaling pathway. Di-
rect binding of GIV’s SH2-like domain to 
pY1148 on EGFR tail competes with 
binding of Shc1, a major adaptor and a 
bona fide activator of Ras-MAPK/ERK 
signaling (Sakaguchi et al., 1998). In cells 
or GIV siRNA as indicated. Fixed cells were 
costained with phalloidin–Texas red (F-actin, 
red) and DAPI (DNA, blue) and visualized by 
confocal microscopy. Stress fibers were 
reduced when endogenous GIV was 
depleted in control, HeLa GIV-FA (f), and 
HeLa GIV-RL (h) cells but not in HeLa GIV-WT 
cells. Both HeLa GIV-FA and GIV-RL cells 
show a paucity of stress fibers even without 
depletion of endogenous GIV (e, g), 
indicating that these GIV mutants have a 
dominant negative effect on actin 
remodeling. Bar, 10 μM. (e) HeLa control or 
HeLa GIV-WT and GIV-RL cells expressing 
various siRNA-resistant GIV constructs were 
treated with scrambled or GIV siRNA as in d. 
Cell migration was determined as described 
in Materials and Methods. Depletion of GIV 
inhibited migration in control and HeLa 
GIV-RL cells but not in HeLa GIV-WT cells.
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mechanism by which multiple oncogenic RTKs (IGF1R, EGFR, and 
VEGFR) modulate signals via GIV. On the basis of our findings in cells 
expressing the SH2-deficient GIV mutant, we conclude that the 
RTK:GIV interface and, more specifically, GIV’s SH2-like domain are 
effective and attractive targets for antimetastatic therapy because of 
two outstanding reasons: 1) selective inhibition of this interaction 
effectively abolishes aberrant activation of PI3K downstream of mul-
tiple RTKs via GIV, promotes rapid dephosphorylation of receptor, 
and inhibits cell migration, indicating that this is a sensitive target; 
and 2) GIV’s SH2-like domain is unique when compared with other 
known SH2 domains, in that the sequence similarity is weak despite 
similarities in folding and mechanism of phosphotyrosine recogni-
tion. Whereas most SH2 domains can be expressed in bacteria in the 
absence of phosphotyrosine ligands and have stable folding pat-
terns identifiable by far-ultraviolet circular dichroism spectroscopy 
(Williams and Shoelson, 1993; Haan et al., 1999; Arold et al., 2001), 
GIV’s SH2-like domain is intrinsically disordered in the resting state 
and folded exclusively after phosphotyrosine ligand binding. Multi-
ple strategies for cloning and expressing GIV’s ∼110-aa-long SH2-
like domain failed, each time yielding several breakdown products 
and little or no protein of expected size, although a larger C-termi-
nus could be expressed in bacteria (in vitro pull-down assays) and 
the SH2-like domain alone could be expressed in mammalian cells 
(BiFC assays) as stable and functional products. This suggests that 
the isolated SH2-like domain of GIV, when expressed alone in bacte-
ria, is disordered and unstable and may require ligand binding and/
or flanking regions within GIV’s C-terminus or other cellular proteins 
for folding and/or stability and functional integrity. We conclude that 
unlike most SH2 domains, GIV’s SH2-like domain presents unique 
features that could provide specificity when targeting the GIV:RTK 
interface. Based on our findings, it is likely that use of small mole-
cules against GIV-SH2 has the potential of being both selective and 
broad, selectively inhibiting GIV-dependent prometastatic growth 
factor signaling, yet acting broadly downstream of multiple RTKs.
Multimodular cooperation in GIV allows signal integration 
downstream of multiple RTKs via G protein intermediates
Besides this unique coexistence of GEF and SH2-like domains, GIV 
contains a growing list of many other of domains/motifs, coopera-
tion between which could also be critical for its function as signal 
transducer (Figure 8). Here we demonstrated that GIV’s GEF and 
SH2-like domains cooperate in the formation of RTK-GIV-Gαi ter-
nary complexes and subsequent activation of Gαi. We also provided 
evidence that cooperation between GIV’s SH2-like domain and its 
phosphotyrosines is essential for the formation of RTK-GIV-PI3K ter-
nary complexes and subsequent activation of the PI3K/Akt pathway. 
That cells expressing SH2-deficient GIV mutants poorly remodel ac-
tin also suggests that SH2-like and actin-binding domains of GIV 
cooperate in linking EGF signaling to actin remodeling. It is likely 
that there are many more interdomain collaborations with the new 
discovered SH2-like domain—for example, the observed recruit-
ment of GIV to the PM after growth factor stimulation is likely to be 
cooperatively mediated by its phosphatidylinositol 4-phosphate 
(PI4P) binding (Enomoto et al., 2005) and the SH2 domains. The 
coiled-coil domain, which mediates homo-oligomerization (Enomoto 
et al., 2005), could cooperate with the SH2-like domain to enhance 
clustering of RTK-GIV complexes at the PM. We propose that the 
SH2-like domain is key to achieve targeting and proximity of GIV to 
RTKs, which allows GIV to integrate incoming signals from these re-
ceptors and modulate them via activation of G proteins in the vicin-
ity of the receptors. Examples of such interdomain collaborations 
were reported in the case of other multimodular signal transducers 
expressing SH2-deficient GIV mutants, for which GIV is uncou-
pled from EGFR, recruitment of Shc1 to EGFR and, consequently, 
downstream activation of ERK kinase are enhanced. We con-
clude that GIV suppresses the MAPK/ERK pathway in part by 
competitively inhibiting the recruitment of Shc1 to ligand-acti-
vated receptors.
Finally, we show that recruitment of GIV to EGFR is required for 3) 
enhanced receptor autophosphorylation. We found that direct 
binding of GIV-SH2 to pY1173 on the EGFR tail competes with 
binding of SHP-1, which is a key protein tyrosine phosphatase 
(PTP) that dephosphorylates major autophosphorylation sites on 
EGFR tail (Okabayashi et al., 1994). When GIV is uncoupled from 
EGFR in cells expressing SH2-deficient GIV, recruitment of SHP-1 
to EGFR and subsequent tyrosine phosphorylation and activa-
tion of SHP-1 are enhanced, and the major autophosphorylation 
sites on EGFR are rapidly dephosphorylated. We conclude that 
GIV enhances receptor autophosphorylation in part by inhibiting 
the recruitment and subsequent activation of SHP-1. Because 
SHP-1 is also the major PTP that dephosphorylates GIV’s ty-
rosines and antagonizes GIV-dependent PI3K activation (Mittal 
et al., 2011), competitive inhibition of SHP-1 recruitment to 
EGFR-bound complexes at the PM may also delay dephospho-
rylation of GIV and further potentiate PI3K activation via the pre-
viously defined ‘RTK-GIV-PI3K’ axis of signaling.
Besides the aforementioned direct effects of GIV’s interaction 
with EGFR, we also observe that binding of GIV to EGFR is required 
for rapid receptor transit through early endosomes and faster rates 
of receptor degradation. Because receptor signaling and trafficking 
are closely intertwined, it is possible that GIV’s interaction with 
EGFR, which alters some of the earliest steps of receptor signaling 
at the PM, could directly or indirectly contribute to rapid down-reg-
ulation of EGFR through the endolysosomal pathway. Alternatively, 
it is possible that the formation of EGFR:GIV complexes on endo-
somes is required to link growth factor signaling to endosomal mat-
uration (Beas et al., 2012), a key determinant of the duration and 
strength of proliferative signaling from this compartment.
Together the foregoing findings provide mechanistic insights 
into our previously reported observations that GIV enhances EGFR 
autophosphorylation and motogenic (promigratory) PI3K/Akt sig-
nals but suppresses mitogenic MAPK/ERK signals after EGF stimula-
tion, thereby orchestrating a signaling dichotomy (Ghosh et al., 
2010). We previously reported that such selective signal modulation 
allows GIV to skew the overall EGF signaling network in favor of 
persistent migration. Previous work predicted a central role for EGFR 
in creating such a dichotomy: EGFR autophosphorylation is essen-
tial for persistent cell migration but not for mitosis (Chen et al., 
1994a) and decisive signaling pathways that dictate whether cells 
migrate or divide diverge at the immediate postreceptor phase 
(Chen et al., 1994b). Here we pinpointed the level of dichotomy as 
the EGFR:GIV interface assembled by GIV’s SH2-like domain and 
the two phosphotyrosines on the EGFR tail. Such interaction, which 
mediates recruitment of GIV to EGFR, fundamentally alters the pro-
file of adaptors recruited to the ligand-activated receptor and in that 
way shapes major downstream signaling pathways such that cells 
are biased to migrate.
GIV’s SH2-like domain is an effective target to disengage 
GIV-dependent prometastatic signaling from multiple RTKs 
during cancer invasion
Because GIV serves as a bona fide enhancer of tumor invasion/
metastasis in a variety of cancers, our results provide a unifying 
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Cruz Biotechnology, Dallas, TX; for immu-
noprecipitation) raised against the last 19 
amino acids of the C-terminus of GIV. The 
anti-Gαi:GTP (6-F12) monoclonal antibody 
(mAb; Lane et al., 2008) was a generous gift 
from Graeme Milligan (Glasgow, Scotland, 
UK, and subsequently commercially ob-
tained from NewEast Biosciences (King of 
Prussia, PA). Total EGFR was visualized by 
immunofluorescence with mAb #225 raised 
against the ectodomain (a gift from Gordon 
Gill, University of California, San Diego, La 
Jolla, CA; Gill et al., 1984) and by anti-EGFR 
polyclonal antibody (Santa Cruz Biotechnol-
ogy) for immunoblotting. Rabbit monoclo-
nal antibody against Tyr-1764-GIV was gen-
erated and validated in collaboration with 
Spring Biosciences (Pleasanton, CA) and 
Ventana (Tucson, AZ). Mouse monoclonal 
antibodies against phosphotyrosine (pTyr; 
610000; BD Biosciences, San Jose, CA), 
FLAG (Sigma-Aldrich), polyhistidine (Sigma-
Aldrich), phospho-Y845 EGFR (Millipore), 
hemagglutinin (HA; Covance, San Diego, 
CA), EEA1 (BD Biosciences), and tubulin 
(Sigma-Aldrich) were purchased from com-
mercial sources. Rabbit polyclonal antibod-
ies against FLAG (Invitrogen; for immuno-
blotting), GST (Santa Cruz Biotechnology), phospho-Y992 EGFR 
(Cell Signaling), total EGFR (Santa Cruz Biotechnology), Gαi3 (M-14; 
Santa Cruz Biotechnology), phospho-Akt S473 (Cell Signaling), 
pan-Gβ (Santa Cruz Biotechnology), and phospho-ERK 1/2 (Cell 
Signaling) were obtained commercially. Anti-mouse and anti-rabbit 
Alexa 594– and Alexa 488–coupled goat IgG for immunofluores-
cence and phalloidin were purchased from Invitrogen. Goat anti-
rabbit and goat anti-mouse Alexa Fluor 680 or IRDye 800 F(ab′)2 
for immunoblotting were from Li-Cor Biosciences (Lincoln, NE). 
Control mouse and rabbit IgGs for immunoprecipitations were 
purchased from Bio-Rad (Hercules, CA) and Sigma-Aldrich, 
respectively.
Plasmid constructs and mutagenesis
Cloning of Gαi3 and GIV into pGEX-4T-1 or pET28b was described 
previously (Garcia-Marcos et al., 2009). GST-EGFR-T (aa 1046–
1210) was cloned into pGEX-4T-1 as described previously (Garcia-
Marcos et al., 2009). Various GST-EGFR tail peptides used in this 
work was generated by cloning fragments (amino acid boundaries 
indicated in Figure 1B) of human EGFR (GenBank accession num-
ber NM_005228; Protein ID NP_001529) into pGEX-4T-1 between 
BamHI and EcoRI. The boundaries of each peptide were identified 
by the sequence flanking each tyrosine: Y1068 (YINQ), Y1086 
(YHNQ), Y1114 (YLNT), Y1148 (YQQD), and Y1173 (YLRV). Hexa-
histidine (6-His)-tagged human SHP-1 PTP (GenBank accession 
number BC002523) cloned into pET28 expression vector was a 
generous gift from Richard Anderson (University of Wisconsin, 
Madison, WI; Bairstow et al., 2005; Mittal et al., 2011). Shc1 con-
structs were generous gifts from Tony Pawson (Mount Sinai Hospi-
tal, Toronto, Canada). For mammalian expression, C-terminal 
FLAG-tagged GIV was generated by cloning GIV into p3XFLAG-
CMV-14 between NotI and BamHI. RNA interference–resistant 
GIV was generated by silent mutations as described previously 
(Garcia-Marcos et al., 2009). Insulin receptor-HA (Lin et al., 2011) 
that bridge RTKs and small G proteins, such as Ras-GAP (Schlessinger 
and Lemmon, 2003), which inactivates Ras in the vicinity of ligand-
activated receptors.
In conclusion, we defined a structural basis for how GIV, a nonre-
ceptor GEF, forms a novel platform for activation of trimeric Gi pro-
teins in the proximity of RTKs and helps define a new paradigm in 
signal transduction. The mechanistic and structural insights gained 
here not only characterize a new pharmacological target for uncou-
pling GIV from growth factor RTKs, they also shed light on the ob-
served promiscuity and versatility of GIV as a signal transducer, that 
is, its ability to integrate signals downstream of multiple RTKs in a 
variety of cells during diverse cellular processes, such as cancer inva-
sion, angiogenesis, epithelial wound healing, insulin response, cel-
lular autophagy, and so on, all via G protein intermediates.
MATERIALS AND METHODS
Reagents and antibodies
Unless otherwise indicated, all reagents were of analytical grade 
and obtained from Sigma-Aldrich (St. Louis, MO). Cell culture me-
dia were purchased from Invitrogen (Carlsbad, CA). EGF and insulin 
were obtained from Invitrogen and Novagen, respectively. Recom-
binant EGFR (Millipore, Billerica, MA and Cell Signaling, Beverly, 
MA), VEGFR (Cell Signaling), and InsRβ (Sigma-Aldrich) were pur-
chased from commercial sources. Recombinant His-Shc1 protein 
was purchased from Abnova (Taipei City, Taiwan). PP2 was obtained 
from Calbiochem. Silencer Negative Control scrambled (Scr) siRNA 
(Ghosh et al., 2008) was purchased from Ambion (Grand Island, 
NY), and GIV siRNA (Garcia-Marcos et al., 2009; Ghosh et al., 2008, 
2010) was custom ordered from Dharmacon (Lafayette, CO). Anti-
bodies against GIV used in this work include rabbit serum and affin-
ity-purified anti-GIV coiled-coil immunoglobulin G (IgG; GIV-ccAb; 
for immunoblotting only) raised against the coiled-coil domain of 
GIV (Garcia-Marcos et al., 2009; Ghosh et al., 2008, 2010) and affin-
ity-purified anti-Girdin C-terminus (anti–GIV-CT, Girdin T-13; Santa 
FIGURE 8: Multimodular cooperation allows GIV, a class 1 SH2-like adaptor, to link GEF activity 
for trimeric Gαi to cytoplasmic tails of ligand-activated RTKs. Schematic illustration of the 
modular structure of GIV from amino- to carboxyl-terminus: phosphoinositide-binding domain 
(PI4P-BD, brown), which binds membrane lipid and helps localize GIV to the PI4P-enriched 
plasma (PM), where ligand-activated receptors and G proteins are located; a GEF motif (green), 
which binds and activates Gαi; a SH2 domain (blue), which recognizes and docks onto the 
autophosphorylation sites on cytoplasmic tails of ligand-activated EGFR and other RTKs; a pair 
of phosphotyrosines (P), which directly bind p85α (PI3K) and activate class 1A PI3Ks; and an 
actin-binding domain (actin-BD, purple), which binds and remodels actin at the leading edge of 
migrating cells. These binding events cooperatively maintain GIV at the PM such that Gαi and 
PI3K are activated, and actin is remodeled in close proximity to RTKs. Recruitment of GIV-SH2 to 
RTKs and activation of Gαi in the vicinity of activated receptors enable GIV to modulate 
signaling programs downstream of the receptor. The plasticity of GIV’s SH2-like domain 
between a stably folded and partially folded state is likely to regulate GIV’s ability to engage 
with activated RTKs.
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sequence. Of all the models, the one based on the structure of hu-
man SOCS3-SH2 domain (PDB 2hmh) was chosen for further work 
because it had the lowest number of steric conflicts. The model 
was validated by generating a series of mutants that were predicted 
to decrease, increase, or have no effect on the phosphotyrosine-
binding property of GIV-SH2 (Figure 3, a and b). Because of weak 
sequence similarity in the region of the αA helix, we could not com-
putationally resolve an ambiguity in the alignment and conclusively 
state whether GIV K1722 or K1724 participates in coordination of 
the phosphorylated tyrosine on the substrate peptide. Conse-
quently, both residues were mutated to better pinpoint how the 
pTyr-binding pocket is formed.
In vitro and in cellulo phosphorylation assays
In vitro kinase assays were performed using bacterially expressed 
GST-EGFR-tail peptides (∼10–15 μg/reaction) and recombinant 
EGFR kinase. Reactions were started by adding 200–1000 μM ATP 
and carried out at 25°C for 60 min in tyrosine kinase buffer (60 mM 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid [HEPES], pH 7.5, 
5 mM MgCl2, 5 mM MnCl2, 3 μM Na3OV4). Reactions were stopped 
by cooling to 4°C, and the phosphoprotein either was used in GST 
pull-down assays or analyzed by immunoblotting. For in cellulo 
phosphorylation assays on GIV-FLAG, assays were performed ex-
actly as we did previously (Lin et al., 2011). Briefly, FLAG-tagged GIV 
was coexpressed with untagged EGFR, and at 32 h after transfec-
tion, cells were starved for 16 h and preincubated with 100 μM so-
dium orthovanadate for 2 h and the Src inhibitor PP2 (250 nM) for 
1 h before EGF (50 nM) stimulation, exactly as done previously (Lin 
et al., 2011; Mittal et al., 2011). Tyrosine phosphorylation was ana-
lyzed by immunoblotting using anti-pTyr mAb (BD Biosciences).
GST-pull-down assays
These assays were carried out as previously described (Ghosh et al., 
2010). Briefly, purified GST-fused EGFR peptides (15–35 μg) or GST 
alone (30–45 μg) were first phosphorylated by carrying out in vitro 
kinase assays with recombinant EGFR kinase (Invitrogen) and subse-
quently incubated for 2 h at 4°C in binding buffer (50 mM Tris-HCl, 
pH 7.4, 100 mM NaCl, 0.4% [vol/vol] NP-40, 10 mM MgCl2, 5 mM 
EDTA, 2 mM DTT, and 2 mM sodium orthovanadate) containing WT 
or various mutants of His-GIV CT (aa 1660–1870). After 2 h, glutathi-
one S-Sepharose beads (GE Healthcare) was added, and the incu-
bation was carried out for another 4 h at 4°C with constant tumbling. 
The beads were then washed four times, each time with 1 ml of 
wash buffer (4.3 mM Na2HPO4, 1.4 mM KH2PO4, pH 7.4, 137 mM 
NaCl, 2.7 mM KCl, 0.1% [vol/vol] Tween-20, 10 mM MgCl2, 5 mM 
EDTA, 2 mM DTT, and 2 mM sodium orthovanadate), and bound 
proteins were eluted in sample buffer for SDS–PAGE. When GST-
Gαi3 was used in these assays, both binding and wash buffers were 
supplemented with 30 μM GDP. For His-pull-down assays with auto-
phosphorylated RTKs, recombinant RTKs were first autophosphory-
lated by incubation in the presence of Mn and ATP exactly as in ki-
nase assays (Lin et al., 2011) and subsequent incubation with 
His-GIV-CT or His-Sec22 (negative control) proteins for 2 h at 4°C in 
binding buffer that was supplemented with 0.1 mg/ml bovine serum 
albumin (BSA) with constant tumbling. BSA-blocked His-Pur Cobalt 
beads (Pierce) were then added, and the incubation was carried out 
for another 4 h at 4°C.
Cell culture, transfection, lysis, and immunoprecipitation
Unless mentioned otherwise, cell lines used in this work were cul-
tured according to American Type Culture Collection guidelines. 
Transfection was carried out using Genejuice (Novagen) for DNA 
was generated by cloning the human insulin receptor gene 
(GenBank accession number NM_000208) into pcDNA 3 (Invitro-
gen) and inserting a HA tag at the C-terminus. Purified His-Sec22 
was a generous gift from Susan Ferro-Novick (University of Califor-
nia, San Diego, La Jolla, CA).
Multiple mutations on GIV used in this work were generated 
by site-directed mutagenesis using QuikChange kit (Stratagene, 
San Diego, CA) as per the manufacturer’s protocols. All constructs 
were checked by DNA sequencing.
Protein expression and purification
All GST- and His-tagged constructs were expressed and purified 
from Escherichia coli strain BL21 (DE3; Invitrogen) as described pre-
viously (Garcia-Marcos et al., 2009, 2010). Briefly, cultures of trans-
formed bacteria were induced overnight at 25°C with 1 mM isopro-
pyl β-d-1-thiogalactopyranoside, and a bacterial pellet from 1 l of 
culture was resuspended in 10 ml of GST-lysis buffer (25 mM Tris-
HCl, pH 7.5, 20 mM NaCl, 1 mM EDTA, 20% [vol/vol] glycerol, 1% 
[vol/vol] Triton X-100, 2× protease inhibitor cocktail [Complete EDTA-
free; Roche Diagnostics]) or His-lysis buffer (50 mM NaH2PO4, pH 
7.4, 300 mM NaCl, 10 mM imidazole, 1% [vol/vol] Triton X-100, 2× 
protease inhibitor cocktail [Complete EDTA-free, Roche Diagnostics]) 
for GST- or His-fused proteins, respectively. After sonication (4 × 20 s, 
1 min between cycles), lysates were centrifuged at 12,000 × g at 4°C 
for 20 min. Solubilized proteins were affinity purified on glutathione-
Sepharose 4B beads (GE Healthcare) or HisPur Cobalt Resin (Pierce). 
Proteins were eluted, dialyzed overnight against phosphate-buffered 
saline (PBS), and stored at −80°C in aliquots. His-Gαi3 was buffer 
exchanged into G protein storage buffer (20 mM Tris-HCl, pH 7.4, 
200 mM NaCl, 1 mM MgCl2, 1 mM dithiothreitol [DTT], 10 μM GDP, 
5% [vol/vol] glycerol) before storage at −80°C.
Generation of sequence alignment between GIV and 42 
SH2 domains with resolved three-dimensional structures
Three-dimensional structures of 42 SH2 domains were retrieved 
from the Protein Data Bank (PBD; Rose et al., 2011) and their corre-
sponding amino acid sequences from UniProt Knowledgebase 
(www.uniprot.org/help/uniprotkb). The sequence alignment be-
tween these domains was built automatically using the Needleman 
and Wunsch algorithm with zero gap end penalties (ZEGA; Abagyan 
and Batalov, 1997), as implemented in ICM (Abagyan and Totrov, 
1994; Abagyan et al., 1994). The alignment was then adjusted man-
ually with guidance from pairwise structural alignments of the 42 
SH2 domains and subsequently modified to exclude the variable 
loops and retain only the conserved secondary structure elements 
of a canonical SH2 domain. The amino acid sequence of the human 
GIV C-terminus (BAE44387) was aligned against the obtained SH2 
domain structure-sequence alignment by maximizing the total Gon-
net comparison matrix score (Gonnet et al., 1992) of the GIV se-
quence against all 42 sequences in the alignment while not allowing 
gaps in the conserved SH2 domain topological elements. The re-
sulting alignment is shown in Supplemental Figure S1.
Construction of a three-dimensional model of the putative 
SH2 domains in the GIV C-terminus
A tentative model of GIV’s C-terminal putative SH2 domain was 
constructed with the ICM homology modeling procedure (Abagyan 
et al., 1997; Cardozo et al., 1995, 2000) using the available struc-
tures of SH2 domains and the sequence alignment shown in Sup-
plemental Figure S1. The conformation of the loops connecting the 
conserved secondary structure elements was obtained by a search 
in the library of PDB elements with similar terminus topology and 
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serum [FBS], 16 h), and incubated with isobutylmethylxanthine 
(200 μM, 20 min), followed by EGF stimulation (50 nM, 20 min) 
and forskolin (10 μM, 10 min). To stop the reaction, cell medium 
was replaced with 150 μl of ice-cold trichloroacetic acid (TCA) 
7.5% (wt/vol). cAMP content in TCA extracts was determined by 
radioimmunoassay (RIA). Production of cAMP was normalized to the 
amount of protein (determined using a dye-binding protein assay 
[Bio-Rad]) per sample (Ostrom et al., 2001).
Immunofluorescence
These assays were done exactly as previously (Ghosh et al., 2010; 
Garcia-Marcos et al., 2011a), using a confocal Leica SPE micro-
scope. To visualize all populations of receptors in cells, images 
were acquired as Z-stacks and maximally projected. Briefly, cells 
were fixed at room temperature with 3% paraformaldehyde for 
20–25 min, permeabilized (0.2% Triton X-100) for 45 min, and in-
cubated for 1 h each with primary and then secondary antibodies 
as described previously (Ghosh et al., 2008). Antibody dilutions 
were as follows: mAb green fluorescent protein, 1:500; secondary 
goat anti-rabbit (594) and goat anti-mouse (488) Alexa-conjugated 
antibodies, 1:500; and 4′,6-diamidino-2-phenylindole (DAPI), 
1:2000 (Molecular Probes). Samples were examined with a Leica 
SPE confocal microscope (Leica) using a 63× objective, and col-
lected images were processed using ImageJ software (National 
Institutes of Health, Bethesda, MD) and assembled for presenta-
tion using Photoshop and Illustrator software (Adobe).
Bimolecular fluorescence complementation
Constructs used for BiFC assay were generated using Venus, a vari-
ant of YFP that contains a mutation to prevent dimerization (Nagai 
et al., 2002). The C-terminus of Venus YFP (VC) was cloned into NotI 
and XhoI sites of a pcDNA3.1+ vector. This construct expresses 85 
residues of the C-terminus Venus YFP, which also has a C-terminus 
HA tag. The N-terminus of Venus YFP (VN) was cloned into KpnI and 
BamHI sites of a pcDNA3.1+ vector. This construct expresses 173 
residues of the N-terminus Venus YFP with a Myc tag. To generate 
VN-GIV SH2, aa 1714–1815 of human GIV was cloned into the 
BamHI and NotI sites of the VN plasmid. Similarly, to generate 
EGFR-VC, human EGFR was cloned into the HindIII and NotI sites of 
VC plasmid. Venus N-terminus-tagged and C-terminus-tagged (VN 
and VC, respectively) constructs were cotransfected in various com-
binations using Genejuice (EMD Millipore) in Cos7 cells. Cells were 
maintained at steady state (10% FBS/DMEM), fixed, and stained at 
36 h posttransfection with DAPI and imaged using a Leica SPE con-
focal microscope with a 63× objective. All constructs were expressed 
as a full-length protein without proteolysis/breakdown, as confirmed 
by full-length immunoblots.
Wound-healing assays
These assays were performed in the presence of serum exactly as 
described previously (Garcia-Marcos et al., 2009; Ghosh et al., 2010). 
Briefly, monolayers of HeLa cells were scratch-wounded with a 1-mm 
pipette tip, and multiple wound sites were serially photographed at 
12-h intervals. Percentage wound closure was calculated by analyz-
ing the wound area in the serial images, quantified using ImageJ.
Statistical analysis
Each experiment presented in the figures is representative of at least 
three independent experiments. Statistical significance (p value) be-
tween various conditions was assessed with the one-way analysis of 
variance (Bonferroni posthoc test). All graphical data presented were 
prepared using Prism software (GraphPad, La Jolla, CA).
plasmids or Oligofectamine (Invitrogen) for siRNA oligos following 
the manufacturers’ protocols, and stable cell lines were selected as 
mentioned previously (Garcia-Marcos et al., 2009; Ghosh et al., 
2010) using the neomycin analogue G418 (Cellgro). HeLa cell lines 
stably expressing siRNA-resistant GIV-WT (HeLa-GIV-WT), GIV-
F1685A mutant (HeLa-GIV-FA), and GIV-R1745L (HeLa-GIV-RL) were 
generated and maintained in the presence of G418 (500 μg/ml) as 
previously described (Ghosh et al., 2010). Clones were chosen for 
each construct strictly so that they had relatively low abundance of 
exogenously expressed GIV (approximately one to two times the 
abundance of endogenous GIV), so that after depletion of the en-
dogenous GIV protein by siRNA (for 48 h), each stable cell line ex-
pressed physiological levels of siRNA-resistant GIV-WT or mutant 
GIV constructs. For each construct, similar results were obtained 
from two separate clones.
Lysates for immunoprecipitation or pull-down assays were pre-
pared by resuspending cells in lysis buffer (20 mM HEPES, pH 7.2, 
5 mM Mg acetate, 125 mM K acetate, 0.4% Triton X-100, 1 mM 
DTT, supplemented with sodium orthovanadate [500 μM], phos-
phatase (Sigma-Aldrich), and protease [Roche] inhibitor cocktails), 
after which they were passed through a 30-gauge needle at 4°C 
and cleared (10,000–14,000 × g for 10 min) before use in subse-
quent experiments.
For immunoprecipitations, cell lysates (∼1–2 mg of protein) were 
incubated for 4 h at 4°C with 2 μg of anti-FLAG mAb for immunopre-
cipitation of GIV-FLAG, anti-EGFR #225 mAb (Gill et al., 1984) for 
endogenous EGFR, anti-HA mAb (Covance) for immunoprecipitation 
of HA-tagged insulin receptor, and control mouse IgGs where indi-
cated. Protein G agarose beads (GE Healthcare) were added and in-
cubated at 4°C for an additional 60 min. Beads were washed and then 
resuspended and boiled in SDS sample buffer. Buffers were supple-
mented with 1 mM sodium orthovanadate for all steps of the assay.
For immunoprecipitation of active Gαi3, freshly prepared cell 
lysates (2-4 mg) were incubated for 30 min at 4°C with the confor-
mational Gαi3:GTP mouse antibody (1 μg; Lane et al., 2008) or pre-
immune control mouse IgG. Protein G-Sepharose beads (GE Health-
care) were added and incubated at 4°C for additional 30 min (total 
duration of assay is 1 h). Beads were immediately washed three 
times using 1 ml of lysis buffer (composition exactly as before; no 
nucleotides added), and immune complexes were eluted by boiling 
in SDS as previously described (Ghosh et al., 2010).
Steady-state GTPase assay
These assays were done as described previously (Garcia-Marcos 
et al., 2009, 2010, 2011a, 2012). Briefly, 100 nM His-Gαi3 was prein-
cubated with wild-type or R1745L mutant of His-GIV-CT (aa 1660–
1870) for 15 min at 30°C in assay buffer (20 mM Na-HEPES, pH 8, 
100 mM NaCl, 1 mM EDTA, 2 mM MgCl2, 1 mM DTT, 0.05% [wt/vol] 
C12E10). GTPase reactions were initiated at 30°C by adding an equal 
volume of assay buffer containing 1 μM [γ-32P]GTP (∼50 cpm/fmol). 
Duplicate aliquots (50 μl) were removed at 10 min and reactions 
stopped with 950 μl of ice-cold 5% (wt/vol) activated charcoal in 
20 mM H3PO4, pH 3. Samples were then centrifuged for 10 min at 
10,000 × g, and 500 μl of the resultant supernatant was scintillation 
counted to quantify released [32P]Pi. To determine the specific Pi pro-
duced, the background [32P]Pi detected at 10 min in the absence of 
G protein was subtracted from each reaction. The results were ex-
pressed as relative to control (buffer, PBS, without GIV).
Measurement of cAMP
HeLa cells stably expressing GIV-WT or GIV-RL were depleted of 
endogenous GIV using siRNA, serum starved (0.2% fetal bovine 
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